About Interventional Medicine
Biocompatibles, a BTG International group company, is a leader in medical technology and operates in the field of interventional oncology using drug-device combination products. We develop, manufacture and market implantable embolisation and drug-eluting beads that are used in more than 70 countries worldwide for the treatment of primary liver cancer (HCC), liver metastases from colorectal cancer, and other cancers.
We sell three of our products, LC Bead™, LC BeadM1 and Bead Block®, direct to specialist healthcare physicians in the US, and DC Bead®, DC BeadM1 and Bead Block® through distributors in other countries.
A central conviction underpinning our strategy is that core approaches to cancer treatment, namely systemic drug administration and surgery, can be supplemented by a wider use of minimally-invasive, local treatments for locally-dominant disease. The rationale behind locally-delivered therapy is to achieve a better side-effect profile and potentially improved patient survival.
Our aim is to deliver products that are relatively easy for doctors to use; are safe for patients and have clear clinical benefits; and whose value is clear to the hospital administrator and to the ultimate payer.
We have a rich heritage of leadership and innovation in interventional oncology and we are investing in product development and clinical trials to deliver on our shared vision of excellence in interventional medicine.
Biocompatibles International plc was acquired by BTG plc in January 2011. BTG is an international specialist healthcare company that is developing and commercialising products targeting critical care, cancer and other disorders.